Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) EBT (2016 - 2025)

CorMedix (CRMD) has disclosed EBT for 14 consecutive years, with $56.4 million as the latest value for Q4 2025.

  • Quarterly EBT rose 73.52% to $56.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $150.0 million through Dec 2025, up 58021.24% year-over-year, with the annual reading at $150.0 million for FY2025, 58021.24% up from the prior year.
  • EBT hit $56.4 million in Q4 2025 for CorMedix, up from $52.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $56.4 million in Q4 2025 to a low of -$15.9 million in Q1 2024.
  • Historically, EBT has averaged $3.1 million across 5 years, with a median of -$7.2 million in 2021.
  • Biggest five-year swings in EBT: plummeted 50.44% in 2023 and later surged 1993.4% in 2025.
  • Year by year, EBT stood at -$7.8 million in 2021, then decreased by 5.36% to -$8.2 million in 2022, then decreased by 18.7% to -$9.7 million in 2023, then skyrocketed by 433.84% to $32.5 million in 2024, then soared by 73.52% to $56.4 million in 2025.
  • Business Quant data shows EBT for CRMD at $56.4 million in Q4 2025, $52.6 million in Q3 2025, and $20.3 million in Q2 2025.